Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

555
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
555
Prosopagnosia01:24

Prosopagnosia

212
Prosopagnosia, also known as face blindness, is the inability to recognize faces. In severe cases, individuals with prosopagnosia may not recognize close family members, including parents and spouses, by their faces. For instance, someone with prosopagnosia might walk past their child in a crowd, only realizing their mistake upon noticing their child's distinctive backpack or favorite jacket. Prosopagnosia specifically impairs facial recognition, while the recognition of other objects or...
212
Brain Imaging01:14

Brain Imaging

270
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans),  magnetic resonance imaging (MRI),  functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
270
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

232
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
232

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Network embedding framework for driver gene discovery by combining functional and structural information.

BMC genomics·2023
Same author

MGCNRF: Prediction of Disease-Related miRNAs Based on Multiple Graph Convolutional Networks and Random Forest.

IEEE transactions on neural networks and learning systems·2023
Same author

EpiReSIM: A Resampling Method of Epistatic Model without Marginal Effects Using Under-Determined System of Equations.

Genes·2022
Same author

MDSN: A Module Detection Method for Identifying High-Order Epistatic Interactions.

Genes·2022
Same author

BLNIMDA: identifying miRNA-disease associations based on weighted bi-level network.

BMC genomics·2022
Same author

Multi-Objective Artificial Bee Colony Algorithm Based on Scale-Free Network for Epistasis Detection.

Genes·2022

Related Experiment Video

Updated: Aug 3, 2025

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
08:43

Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

Published on: August 7, 2017

8.0K

GCCN: Graph Capsule Convolutional Network for Progressive Mild Cognitive Impairment Prediction and Pathogenesis

Junliang Shang, Qi Zou, Qianqian Ren

    IEEE Journal of Biomedical and Health Informatics
    |April 8, 2023
    PubMed
    Summary

    A new Graph Capsule Convolutional Network (GCCN) predicts mild cognitive impairment to dementia progression by identifying pathogenic factors. This method reveals key disease-related information flows for better understanding and potential intervention.

    More Related Videos

    Using Retinal Imaging to Study Dementia
    09:17

    Using Retinal Imaging to Study Dementia

    Published on: November 6, 2017

    21.7K
    Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
    09:06

    Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

    Published on: June 9, 2018

    12.2K

    Related Experiment Videos

    Last Updated: Aug 3, 2025

    Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment
    08:43

    Application of Granger Causality Analysis of the Directed Functional Connection in Alzheimer's Disease and Mild Cognitive Impairment

    Published on: August 7, 2017

    8.0K
    Using Retinal Imaging to Study Dementia
    09:17

    Using Retinal Imaging to Study Dementia

    Published on: November 6, 2017

    21.7K
    Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease
    09:06

    Whole-brain Segmentation and Change-point Analysis of Anatomical Brain MRI—Application in Premanifest Huntington's Disease

    Published on: June 9, 2018

    12.2K

    Area of Science:

    • Neuroscience
    • Computational Biology
    • Artificial Intelligence

    Background:

    • Mild cognitive impairment (MCI) is a precursor to dementia, necessitating accurate prediction and understanding of its pathogenesis.
    • Identifying key pathogenic factors and their interactions is crucial for developing effective interventions.
    • Current methods may not fully capture the complex, heterogeneous nature of disease progression.

    Purpose of the Study:

    • To propose a novel Graph Capsule Convolutional Network (GCCN) for predicting MCI to dementia progression.
    • To identify the underlying pathogenesis and key risk factors involved in disease development.
    • To leverage heterogeneous pathogenic information for a more comprehensive disease model.

    Main Methods:

    • Constructed heterogeneous pathogenic information association graphs using risk genes and brain regions as nodes.
    • Developed graph capsules by projecting information into disentangled latent components representing format and intensity.
    • Employed GCCN to model information flow among pathogenic factors and identify disease-driving pathways via dynamic routing.

    Main Results:

    • GCCN demonstrated significant advancements over existing methods on public datasets.
    • The identified pathogenic factors were evidential and strongly correlated with progressive MCI.
    • The dynamic routing mechanism successfully captured discriminative pathogenic information flows.

    Conclusions:

    • GCCN offers a powerful new approach for predicting MCI to dementia progression.
    • The method effectively identifies key pathogenic factors and elucidates disease mechanisms.
    • This work provides a foundation for developing targeted diagnostic and therapeutic strategies.